RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-145208 | Pharmaceuticals and Medical
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Relapsing Acute Myeloid Leukemia Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET
7.1 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA RELAPSING ACUTE MYELOID LEUKEMIA DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 4SC AG
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 AbbVie Inc
16.3 Actinium Pharmaceuticals, Inc
16.4 Agios Pharmaceuticals, Inc
16.5 Amgen Inc
16.6 Arog Pharmaceuticals, Inc
16.7 Array BioPharma Inc
16.8 Astellas Pharma Inc
16.9 Astex Pharmaceuticals, Inc
16.10 AstraZeneca Plc
16.11 AVEO Pharmaceuticals, Inc
16.12 BioLineRx, Ltd
16.13 Boehringer Ingelheim GmbH
16.14 Boston Biomedical, Inc
16.15 Bristol-Myers Squibb Company
16.16 Calithera Biosciences, Inc
16.17 Celgene Corporation
16.18 Cornerstone Pharmaceuticals, Inc
16.19 CTI BioPharma Corp
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeANK Project
AT-9283
BI-836858
Bimetinib
BL-8040
other
By Application
clinic
hospital
other
Companies
4SC AG
AbbVie Inc
Actinium Pharmaceuticals, Inc
Agios Pharmaceuticals, Inc
Amgen Inc
Arog Pharmaceuticals, Inc
Array BioPharma Inc
Astellas Pharma Inc
Astex Pharmaceuticals, Inc
AstraZeneca Plc
AVEO Pharmaceuticals, Inc
BioLineRx, Ltd
Boehringer Ingelheim GmbH
Boston Biomedical, Inc
Bristol-Myers Squibb Company
Calithera Biosciences, Inc
Celgene Corporation
Cornerstone Pharmaceuticals, Inc
CTI BioPharma Corp
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.